美国胃肠病医生使用中枢神经调节剂治疗肠易激综合征的调查
一项针对美国525名胃肠病医生的23题问卷调查显示,医生对肠易激综合征患者使用中枢神经调节剂的中位比例为21%-30%,55%认为其非常重要,仅27%认为对多数患者有效。学术机构执业、专注脑-肠互动障碍及感知有效性是高处方行为的显著预测因素,专家处方比例更高且更常认为有效,副作用担忧是最常见障碍。
要点
- 美国胃肠病医生对IBS患者中枢神经调节剂处方中位比例为21%-30%。
- 学术执业、专注脑-肠互动障碍及感知有效性预测高处方行为。
- 专家较普通医生处方比例更高且更常认为有效,副作用担忧是主要障碍。
核心结论
- 多数美国胃肠病医生认为中枢神经调节剂治疗IBS重要,但仅27%认为对多数患者有效。
- 高处方者多处于学术机构、专注IBS且感知药物有效,需教育改善处方行为。
研究设计与样本
- 向美国胃肠病医生发放23题问卷调查,比较高低处方者及医生与专家的处方实践。
- 采用描述性统计和多变量逻辑回归分析,共525名胃肠病医生完成调查。
主要发现
- 525名医生对IBS患者使用中枢神经调节剂的中位范围为21%-30%。
- 55%的临床医生认为中枢神经调节剂在管理IBS中极其/非常重要。
- 高处方行为的显著预测因素:学术vs临床实践(OR 2.60 [95% CI 1.61-4.20])、脑-肠互动障碍专注实践(OR 4.80 [2.60-8.84])、感知有效性更高(OR 2.75 [1.30-5.84])。
- 专家较胃肠病医生处方给更高比例IBS患者(41%-50% vs 21%-30%;P=0.019)且更常认为有效(70% vs 27%;P=0.003)。
- 副作用担忧是使用中枢神经调节剂最常见障碍(59%)。
临床怎么用
- 胃肠病医生应提高对中枢神经调节剂治疗IBS的认识,尤其在非学术及非专注脑-肠互动障碍的实践中。
- 需开展教育以改善处方行为,并关注副作用管理以减少障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Central neuromodulators are an effective treatment for irritable bowel syndrome (IBS) but may be used less frequently than other therapies. AIMS: To survey gastroenterologists in the United States (US) about their use of neuromodulators in patients with IBS. METHODS: A 23-question survey was distributed to gastroenterologists in the United States. Comparisons in prescribing practices were conducted between (a) gastroenterologists who were "high prescribers" versus "low prescribers" of neuromodulators in patients with IBS and (b) gastroenterologists and "gastroenterology experts" in the use of neuromodulators using descriptive statistics and multivariable logistic regression analyses. RESULTS: The 525 gastroenterologists who were surveyed used neuromodulators for a median range of 21%-30% of their patients with IBS. Neuromodulators were described as extremely/very important in managing IBS by 55% of clinicians. Significant predictors of high-prescribing behaviour were academic versus clinical practice setting (odds ratio [OR] 2.60 [95% CI 1.61-4.20]), disorders of brain-gut interaction focused practice (OR 4.80 [2.60-8.84]), and greater perceived effectiveness of neuromodulators (OR 2.75 [1.30-5.84]). Compared to gastroenterologists, experts prescribed neuromodulators to a higher percentage of their patients with IBS (41%-50% vs 21%-30%; P = 0.019) and more frequently found neuromodulators effective (70% vs 27%; P = 0.003). However, concern about side effects was the most common barrier to neuromodulator use (59%). CONCLUSIONS: The majority of US gastroenterologists believe central neuromodulators are important in treating IBS, and 27% believe they are effective in most patients. High prescribers are in academic practice, focus in IBS and perceive central neuromodulators as effective. Education is needed to improve gastroenterologists' prescribing behaviour.
引用
- Nulsen B, LeBrett W, Drossman DA, et al. A survey of gastroenterologists in the United States on the use of central neuromodulators for treating irritable bowel syndrome. Aliment Pharmacol Ther. 2021. PMID: 34148256. doi:10.1111/apt.16467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。